Immune checkpoint inhibitors in ovarian cancer: where do we go from here?

Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy, and despite advancements in therapeutics, most women unfortunately still succumb to their disease. Immunotherapies, in particular immune checkpoint inhibitors (ICI), have been therapeutically transformative in many tumour...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Won-Hee, DeFazio, Anna, Kasherman, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344730/
https://www.ncbi.nlm.nih.gov/pubmed/37457131
http://dx.doi.org/10.20517/cdr.2023.13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344730/
https://www.ncbi.nlm.nih.gov/pubmed/37457131
http://dx.doi.org/10.20517/cdr.2023.13

Ejemplares similares